The Rise of Gene Therapies in Neurological Diseases
In the recent years, the level of interest in Gene Therapy from both industry and academia has been unparalleled. CNS disorders in particular have gained a lot of attention with a considerable emphasis on neurological targets; and this is especially visible when analysing several high-profile deals that occurred in 2018. The biggest stand-out deal was struck by Novartis, buying AveXis for $8.7 billion giving the Basel based biopharma company access to what could potentially be the first one-time only treatment for Spinal Muscular Atrophy (SMA). On top of this, AveXis will also give Novartis access to a promising platform technology based around a non-replicating adeno-associated virus (AAV) capsid that allows penetratration of the blood brain barrier.
The Rise of Gene Therapies in Neurological Diseases
Download Request
Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?
Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs which target specific mutations such as EGFR and ALK have been at the forefront and this has been further supplemented with the application of anti-PD-1/PD-L1 agents (as monotherapies or in combination) where Merck’s Keytruda® (Pembrolizumab) has been leading the charge. In fact, ASCO 2018 has solidified Merck’s dominant position in first line settings.
Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?
Download Request
Key Questions When Doing a Deal with Big Pharma: A Conversation with PharmaVentures (한국어 버전)
What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of the West? Join Adrian Dawkes, Managing Director and Summer Park, Business Development Director for an exclusive discussion on doing deals with big pharma.